Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy

Handbook of Experimental Pharmacology

Volumn 203, Issue , 2011, Pages 127-146

  Wang, Minghan ^a  

^a AMGEN INC   (United States)

Author keywords

11 Hydroxysteroid dehydrogenase; Cortisol; Cushing's syndrome; Glucocorticoid excess; HPA axis; Metabolic syndrome

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; ANTIDIABETIC AGENT; CARBENOXOLONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLYCYRRHETINIC ACID; HYDROCORTISONE; INCB 13739; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; OXIDOREDUCTASE INHIBITOR; PF 915275; UNCLASSIFIED DRUG; ENZYME INHIBITOR;

BIOCHEMISTRY; CORTICOSTEROID METABOLISM; CUSHING SYNDROME; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HORMONE ACTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ANIMAL; DIABETES MELLITUS; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; DIABETES MELLITUS; ENZYME INHIBITORS; GLUCOCORTICOIDS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICE;

EID: 79955606910     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-17214-4_6     Document Type: Review

References (95)

1. Agarwal AK, Mune T, Monder C, White PC (1995) Mutations in putative glycosylation sites of rat 11β-hydroxysteroid dehydrogenase affect enzymatic activity. Biochim Biophys Acta 1248:70-74
2. Ahmed A, Saksena S, Sherlock M, Olliff SP, Elias E, Stewart PM (2008) Induction of hepatic 11β-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease. Clin Endocrinol (Oxf) 68:898-903 (Pubitemid 351703941)
3. Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, Ronquist-Nii Y, Ohman B, Abrahmsen L (2002) Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45:1528-1532 (Pubitemid 35352046)
4. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Bjorkstrand E, Abrahmsen LB (2003) Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144:4755-4762 (Pubitemid 37378389)
5. Andrews RC, Rooyackers O, Walker BR (2003) Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 88:285-291 (Pubitemid 36115179)
6. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593-5602 (Pubitemid 38033020)
7. Barf T, Vallgarda J, Emond R, Haggstrom C, Kurz G, Nygren A, Larwood V, Mosialou E, Axelsson K, Olsson R, Engblom L, Edling N, Ronquist-Nii Y, Ohman B, Alberts P, Abrahmsen L (2002) Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J Med Chem 45:3813-3815 (Pubitemid 35024284)
8. Berthiaume M, Laplante M, Festuccia W, Gelinas Y, Poulin S, Lalonde J, Joanisse DR, Thieringer R, Deshaies Y (2007a) Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology 148:2391-2397 (Pubitemid 46997032)
9. Berthiaume M, Laplante M, Festuccia WT, Cianflone K, Turcotte LP, Joanisse DR, Olivecrona G, Thieringer R, Deshaies Y (2007b) 11β-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Am J Physiol Endocrinol Metab 293:E1045-E1052 (Pubitemid 47535836)
10. Berthiaume M, Laplante M, Festuccia WT, Berger JP, Thieringer R, Deshaies Y (2010) Preliminary report: pharmacologic 11βeta-hydroxysteroid dehydrogenase type 1 inhibition increases hepatic fat oxidation in vivo and expression of related genes in rats fed an obesogenic diet. Metabolism 59:114-117
11. Bhat BG, Hosea N, Fanjul A, Herrera J, Chapman J, Thalacker F, Stewart PM, Rejto PA (2008) Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4′-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11β- hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. J Pharmacol Exp Ther 324:299-305 (Pubitemid 350294164)
12. Blum A, Martin HJ, Maser E (2000) Human 11β-hydroxysteroid dehydrogenase type 1 is enzymatically active in its nonglycosylated form. Biochem Biophys Res Commun 276:428-434
13. Bujalska I, Shimojo M, Howie A, Stewart PM (1997) Human 11β-hydroxysteroid dehydrogenase: studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue. Steroids 62:77-82 (Pubitemid 27066989)
14. Cameron OG, Thomas B, Tiongco D, Hariharan M, Greden JF (1987) Hypercortisolism in diabetes mellitus. Diab Care 10:662-664 (Pubitemid 17158944)
15. Carr A, Cooper DA (2000) Adverse effects of antiretroviral therapy. Lancet 356:1423-1430
16. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D (2001) Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 86:3568-3573 (Pubitemid 32755945)
17. Courtney R, Stewart PM, Toh M, Ndongo MN, Calle RA, Hirshberg B (2008) Modulation of 11β-hydroxysteroid dehydrogenase (11βHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11βHSD1 inhibitor. J Clin Endocrinol Metab 93:550-556 (Pubitemid 351240830)
18. Davis GF (1986) Adverse effects of corticosteroids: II. Systemic. Clin Dermatol 4:161-169
19. Delbende C, Delarue C, Lefebvre H, Bunel DT, Szafarczyk A, Mocaer E, Kamoun A, Jegou S, Vaudry H (1992) Glucocorticoids, transmitters and stress. Br J Psychiatry Suppl 15:24-35
20. Diederich S, Grossmann C, Hanke B, Quinkler M, Herrmann M, Bahr V, Oelkers W (2000) In the search for specific inhibitors of human 11β-hydroxysteroid-dehydrogenases (11β-HSDs): chenodeoxycholic acid selectively inhibits 11β-HSD-I. Eur J Endocrinol 142:200-207
21. Drake AJ, Livingstone DE, Andrew R, Seckl JR, Morton NM, Walker BR (2005) Reduced adipose glucocorticoid reactivation and increased hepatic glucocorticoid clearance as an early adaptation to high-fat feeding in Wistar rats. Endocrinology 146:913-919 (Pubitemid 40129849)
22. Dunn JF, Nisula BC, Rodbard D (1981) Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 53:58-68 (Pubitemid 13245381)
23. Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, Lombardi G, Colao A (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88:2527-2533 (Pubitemid 36724418)
24. Findling JW, Raff H (2005) Screening and diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am 34:385-402, ix-x
25. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356-359 (Pubitemid 34251969)
26. Gallant C, Kenny P (1986) Oral glucocorticoids and their complications. A review. J Am Acad Dermatol 14:161-177 (Pubitemid 16068063)
27. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433-438
28. Hale C, Veniant M, Wang Z, Chen M, McCormick J, Cupples R, Hickman D, Min X, Sudom A, Xu H, Matsumoto G, Fotsch C, St. Jean DJ Jr, Wang M (2008) Structural characterization and pharmacodynamic effects of an orally active 11β-hydroxysteroid dehydrogenase type 1 inhibitor. Chem Biol Drug Des 71:36-44
29. Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC (2001) Intracellular regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase (11β-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11β-HSD-1-deficient mice. Endocrinology 142:114-120 (Pubitemid 32183672)
30. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R (2005) 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202:517-527
31. Hosfield DJ, Wu Y, Skene RJ, Hilgers M, Jennings A, Snell GP, Aertgeerts K (2005) Conformational flexibility in crystal structures of human 11β-hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation. J Biol Chem 280:4639-4648 (Pubitemid 40288633)
32. Hult M, Jornvall H, Oppermann UC (1998) Selective inhibition of human type 1 11β-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics. FEBS Lett 441:25-28 (Pubitemid 29012365)
33. Incyte (2007) Incyte corporation presentation. 2007 UBS global life sciences conference
34. Incyte (2008) Incyte presentation. 26th annual JPMorgan healthcare conference
35. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab Care 24:683-689 (Pubitemid 32893993)
36. Jacobson PB, von Geldern TW, Ohman L, Osterland M, Wang J, Zinker B, Wilcox D, Nguyen PT, Mika A, Fung S, Fey T, Goos-Nilsson A, Grynfarb M, Barkhem T, Marsh K, Beno DW, Nga- Nguyen B, Kym PR, Link JT, Tu N, Edgerton DS, Cherrington A, Efendic S, Lane BC, Opgenorth TJ (2005) Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes. J Pharmacol Exp Ther 314:191-200 (Pubitemid 41058255)
37. Jamieson PM, Chapman KE, Edwards CR, Seckl JR (1995) 11β- hydroxysteroid dehydrogenase is an exclusive 11β- reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 136:4754-4761 (Pubitemid 3002167)
38. Jamieson A, Wallace AM, Andrew R, Nunez BS, Walker BR, Fraser R, White PC, Connell JM (1999) Apparent cortisone reductase deficiency: a functional defect in 11β-hydroxysteroid dehydrogenase type 1. J Clin Endocrinol Metab 84:3570-3574 (Pubitemid 30645207)
39. Jamieson PM, Walker BR, Chapman KE, Andrew R, Rossiter S, Seckl JR (2000) 11β-hydroxysteroid dehydrogenase type 1 is a predominant 11β-reductase in the intact perfused rat liver. J Endocrinol 165:685-692 (Pubitemid 30407697)
40. Kannisto K, Pietilainen KH, Ehrenborg E, Rissanen A, Kaprio J, Hamsten A, Yki-Jarvinen H (2004) Overexpression of 11β-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab 89:4414-4421 (Pubitemid 39244448)
41. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS (2005) Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54:1023-1031 (Pubitemid 40446315)
42. Kim KW, Wang Z, Busby J, Tsuruda T, Chen M, Hale C, Castro VM, Svensson S, Nybo R, Xiong F, Wang M (2006) The role of tyrosine 177 in human 11β-hydroxysteroid dehydrogenase type 1 in substrate and inhibitor binding: an unlikely hydrogen bond donor for the substrate. Biochim Biophys Acta 1764:824-830 (Pubitemid 44419340)
43. Kim KW, Wang Z, Busby J, Tsuruda T, Chen M, Hale C, Castro VM, Svensson S, Nybo R, Xiong F, Wang M (2007) The selectivity of tyrosine 280 of human 11β-hydroxysteroid dehydrogenase type 1 in inhibitor binding. FEBS Lett 581:995-999
44. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ (1997) 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94:14924-14929 (Pubitemid 28041476)
45. Lamberts SW, Koper JW, de Jong FH (1991) The endocrine effects of long-term treatment with mifepristone (RU 486). J Clin Endocrinol Metab 73:187-191 (Pubitemid 21901119)
46. Laue L, Lotze MT, Chrousos GP, Barnes K, Loriaux DL, Fleisher TA (1990) Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects. J Clin Endocrinol Metab 71:1474-1480 (Pubitemid 120032762)
47. Lee ZS, Chan JC, Yeung VT, Chow CC, Lau MS, Ko GT, Li JK, Cockram CS, Critchley JA (1999) Plasma insulin, growth hormone, cortisol, and central obesity among young Chinese type 2 diabetic patients. Diab Care 22:1450-1457 (Pubitemid 29418238)
48. Liu Y, Nakagawa Y, Wang Y, Li R, Li X, Ohzeki T, Friedman TC (2003) Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes 52:1409-1416 (Pubitemid 36666195)
49. Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ, Walker BR (2000a) Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141:560-563 (Pubitemid 32250479)
50. Livingstone DE, Kenyon CJ, Walker BR (2000b) Mechanisms of dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. J Endocrinol 167:533-539 (Pubitemid 32047561)
51. Lloyd DJ, Helmering J, Cordover D, Bowsman M, Chen M, Hale C, Fordstrom P, Zhou M, Wang M, Kaufman SA, Véniant MM (2009) Antidiabetic effects of 11βeta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis. Diabetes Obes Metab 11:688-699
52. Mai K, Andres J, Bobbert T, Maser-Gluth C, Mohlig M, Bahr V, Pfeiffer AF, Spranger J, Diederich S (2007) Rosiglitazone decreases 11β-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue. Clin Endocrinol (Oxf) 67:419-425 (Pubitemid 47283841)
53. Maser E, Volker B, Friebertshauser J (2002) 11β-hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry 41:2459-2465 (Pubitemid 34160910)
54. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170 (Pubitemid 33150673)
55. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS (2003) Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 112:83-90 (Pubitemid 38056379)
56. Miller KK, Daly PA, Sentochnik D, Doweiko J, Samore M, Basgoz NO, Grinspoon SK (1998) Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 27:68-72
57. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, Seckl JR (2001) Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276:41293-41300
58. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR (2004a) Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53:931-938 (Pubitemid 38436604)
59. Morton NM, Ramage L, Seckl JR (2004b) Down-regulation of adipose 11β-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease. Endocrinology 145:2707-2712 (Pubitemid 38686218)
60. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL (1985) Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61:536-540
61. Nuotio-Antar AM, Hachey DL, Hasty AH (2007) Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab 293:E1517-E1528 (Pubitemid 350255101)
62. Obeyesekere VR, Trzeciak WH, Li KX, Krozowski ZS (1998) Serines at the active site of 11β-hydroxysteroid dehydrogenase type I determine the rate of catalysis. Biochem Biophys Res Commun 250:469-473 (Pubitemid 28463903)
63. Oltmanns KM, Dodt B, Schultes B, Raspe HH, Schweiger U, Born J, Fehm HL, Peters A (2006) Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur J Endocrinol 154:325-331
64. Oppermann UC, Netter KJ, Maser E (1995) Cloning and primary structure of murine 11β-hydroxysteroid dehydrogenase/microsomal carbonyl reductase. Eur J Biochem 227:202-208
65. Oppermann U, Filling C, Hult M, Shafqat N, Wu X, Lindh M, Shafqat J, Nordling E, Kallberg Y, Persson B, Jornvall H (2003) Short-chain dehydrogenases/reductases (SDR): the 2002 update. Chem Biol Interact 143-144:247-253 (Pubitemid 36253589)
66. Ozols J (1995) Lumenal orientation and post-translational modifications of the liver microsomal 11β-hydroxysteroid dehydrogenase. J Biol Chem 270:2305-2312
67. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ (2004) Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 101:7088-7093 (Pubitemid 38596447)
68. Phillipou G, Higgins BA (1985) A new defect in the peripheral conversion of cortisone to cortisol. J Steroid Biochem 22:435-436 (Pubitemid 15089151)
69. Pont A, Graybill JR, Craven PC, Galgiani JN, Dismukes WE, Reitz RE, Stevens DA (1984) Highdose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 144:2150-2153 (Pubitemid 15215501)
70. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR (2001) Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86:1418-1421 (Pubitemid 32323037)
71. Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T (2002) Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87:3330-3336 (Pubitemid 34816385)
72. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607
73. Richards S, Sorensen B, Jae HS, Winn M, Chen Y, Wang J, Fung S, Monzon K, Frevert EU, Jacobson P, Sham H, Link JT (2006) Discovery of potent and selective inhibitors of 11β-HSD1 for the treatment of metabolic syndrome. Bioorg Med Chem Lett 16:6241-6245 (Pubitemid 44709906)
74. Rohde JJ, Pliushchev MA, Sorensen BK, Wodka D, Shuai Q, Wang J, Fung S, Monzon KM, Chiou WJ, Pan L, Deng X, Chovan LE, Ramaiya A, Mullally M, Henry RF, Stolarik DF, Imade HM, Marsh KC, Beno DW, Fey TA, Droz BA, Brune ME, Camp HS, Sham HL, Frevert EU, Jacobson PB, Link JT (2007) Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11β-hydroxysteroid dehydrogenase type 1 inhibitors. J Med Chem 50:149-164 (Pubitemid 46105507)
75. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huber R (2010) The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diab Care 33(7):1516-1522
76. Sampath-Kumar R, Yu M, Khalil MW, Yang K (1997) Metyrapone is a competitive inhibitor of 11β-hydroxysteroid dehydrogenase type 1 reductase. J Steroid Biochem Mol Biol 62:195-199 (Pubitemid 27475146)
77. Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR, Seckl JR (2004) 11β-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA 101:6734-6739 (Pubitemid 38586043)
78. Sonino N (1987) The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 317:812-818
79. Sorensen B, Rohde J, Wang J, Fung S, Monzon K, Chiou W, Pan L, Deng X, Stolarik D, Frevert EU, Jacobson P, Link JT (2006) Adamantane 11-β-HSD-1 inhibitors: application of an isocyanide multicomponent reaction. Bioorg Med Chem Lett 16:5958-5962 (Pubitemid 44755304)
80. St Jean DJ Jr, Yuan C, Bercot EA, Cupples R, Chen M, Fretland J, Hale C, Hungate RW, Komorowski R, Veniant M, Wang M, Zhang X, Fotsch C (2007) 2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11β-hydroxysteriod dehydrogenase type 1. J Med Chem 50:429-432 (Pubitemid 46239777)
81. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH (1999) Cortisol metabolism in human obesity: impaired cortisone- > cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84:1022-1027 (Pubitemid 29138237)
82. Tomlinson JW, Draper N, Mackie J, Johnson AP, Holder G, Wood P, Stewart PM (2002) Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. J Clin Endocrinol Metab 87:57-62 (Pubitemid 34084671)
83. Tomlinson JW, Sherlock M, Hughes B, Hughes SV, Kilvington F, Bartlett W, Courtney R, Rejto P, Carley W, Stewart PM (2007) Inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab 92:857-864 (Pubitemid 46465655)
84. van Schaftingen E, Gerin I (2002) The glucose-6-phosphatase system. Biochem J 362:513-532
85. Veilleux A, Rhéaume C, Daris M, Luu-The V, Tchernof A (2009) Omental adipose tissue type 1 11 beta-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women. J Clin Endocrinol Metab 94:3550-3557
86. Véniant MM, Hale C, Komorowski R, Chen MM, St. Jean DJ Jr, Fotsch C, Wang M (2009) Time of the day for 11β-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice. Diabetes Obes Metab 11:109-117
87. von Geldern TW, Tu N, Kym PR, Link JT, Jae HS, Lai C, Apelqvist T, Rhonnstad P, Hagberg L, Koehler K, Grynfarb M, Goos-Nilsson A, Sandberg J, Osterlund M, Barkhem T, Hoglund M, Wang J, Fung S, Wilcox D, Nguyen P, Jakob C, Hutchins C, Farnegardh M, Kauppi B, Ohman L, Jacobson PB (2004) Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes. J Med Chem 47:4213-4230 (Pubitemid 39056076)
88. Wake DJ, Rask E, Livingstone DE, Soderberg S, Olsson T, Walker BR (2003) Local and systemic impact of transcriptional up-regulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 88:3983-3988 (Pubitemid 37034555)
89. Walker EA, Stewart PM (2003) 11β-hydroxysteroid dehydrogenase: unexpected connections. Trends Endocrinol Metab 14:334-339
90. Walker BR, Campbell JC, Fraser R, Stewart PM, Edwards CR (1992) Mineralocorticoid excess and inhibition of 11β-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf) 37:483-492
91. Walker EA, Clark AM, Hewison M, Ride JP, Stewart PM (2001) Functional expression, characterization, and purification of the catalytic domain of human 11-β -hydroxysteroid dehydrogenase type 1. J Biol Chem 276:21343-21350
92. Walker EA, Ahmed A, Lavery GG, Tomlinson JW, Kim SY, Cooper MS, Ride JP, Hughes BA, Shackleton CH, McKiernan P, Elias E, Chou JY, Stewart PM (2007) 11β-Hydroxysteroid dehydrogenase type 1 regulation by intracellular glucose 6-phosphate provides evidence for a novel link between glucose metabolism and hypothalamo-pituitary-adrenal axis function. J Biol Chem 282:27030-27036 (Pubitemid 47501934)
93. Yau JL, Noble J, Kenyon CJ, Hibberd C, Kotelevtsev Y, Mullins JJ, Seckl JR (2001) Lack of tissue glucocorticoid reactivation in 11β -hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc Natl Acad Sci USA 98:4716-4721
94. Zhang J, Osslund TD, Plant MH, Clogston CL, Nybo RE, Xiong F, Delaney JM, Jordan SR (2005) Crystal structure of murine 11β-hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes. Biochemistry 44:6948-6957 (Pubitemid 40632413)
95. Zinker B, Mika A, Nguyen P, Wilcox D, Ohman L, von Geldern TW, Opgenorth T, Jacobson P (2007) Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance. Metabolism 56:380-387 (Pubitemid 46217803)